What is the difference between delayed gastric emptying and gastroparesis?

Delayed gastric emptying is a measurement: food leaves the stomach more slowly. Every GLP-1 receptor agonist produces it, and it is part of how the drugs reduce appetite and blunt post-meal glucose. Gastroparesis is a diagnosed syndrome requiring persistent nausea, vomiting, early fullness, bloating and upper abdominal pain, objective evidence of delayed emptying, and exclusion of mechanical obstruction.

Does the Ozempic label mention gastroparesis?

Yes. The label states that Ozempic is not recommended in patients with severe gastroparesis. The postmarketing experience section also lists ileus, intestinal obstruction, and severe constipation including fecal impaction among gastrointestinal adverse reactions.

Which symptoms on Ozempic need a doctor?

Call your prescriber for vomiting that prevents you from keeping fluids down, vomiting food eaten many hours earlier, nausea and fullness that persist beyond two to three weeks at a stable dose, weight loss driven by inability to eat, or signs of dehydration. Seek urgent care for severe abdominal pain radiating to the back, or abdominal pain with vomiting and no passage of stool or gas.

Should you stop Ozempic before surgery or an endoscopy?

Guidance changed in 2024. A multi-society guidance document from the American Society of Anesthesiologists, the American Gastroenterological Association, ASMBS, ISPCOP and SAGES states that most patients can continue GLP-1 receptor agonists before elective surgery, while patients at highest risk of gastrointestinal effects should follow a liquid diet for 24 hours beforehand. Tell your surgeon, anesthesiologist, and endoscopist that you take the medication when the procedure is scheduled.

Does Ozempic Cause Gastroparesis or Stomach Paralysis?

Q: Does Ozempic cause gastroparesis?

Ozempic slows gastric emptying by design; the label states that semaglutide causes a delay of early postprandial gastric emptying. Whether that becomes diagnosed gastroparesis is a separate question. A 2023 JAMA research letter reported an adjusted hazard ratio of 3.67 (95% CI 1.15 to 11.90) for gastroparesis in GLP-1 users compared with people taking bupropion-naltrexone. The confidence interval is wide and the event count was small, so the true magnitude of the risk is uncertain, and the absolute risk is low.

The short answer: slowing the stomach is how Ozempic works, not a malfunction. The label states plainly that semaglutide "causes a delay of early postprandial gastric emptying." A separate question is whether that slowing crosses into diagnosed gastroparesis. One published cohort analysis found a higher rate: a hazard ratio of 3.67 (95% CI 1.15 to 11.90) for gastroparesis in GLP-1 users compared with people taking bupropion-naltrexone. The confidence interval is wide and the number of events was small, so the size of the risk is uncertain. The absolute risk remains low, and the FDA label already advises that Ozempic is not recommended in people with severe gastroparesis.

"Stomach paralysis" is a headline phrase, not a clinical one. The precise terms matter here, so start with them.

Delayed gastric emptying is not the same as gastroparesis

Two different things get collapsed into one word.

Delayed gastric emptying is a measurable slowing of how fast food leaves the stomach. Every GLP-1 receptor agonist does this. It is part of why the drugs work: food stays in the stomach longer, you feel full sooner, and glucose enters the bloodstream more gradually after a meal. It is dose-related and expected.

Gastroparesis is a diagnosed syndrome, not a measurement. It requires a defined set of symptoms, persistent nausea, vomiting, early fullness, bloating, and upper abdominal pain, plus objective evidence of delayed emptying on a gastric emptying study, with mechanical obstruction ruled out. It is a clinical picture that interferes with eating and, for some people, persists.

Almost everyone on semaglutide has the first. A small number develop something resembling the second. Conflating them produces both unnecessary alarm and dismissal of real cases.

What does the FDA label say?

The Ozempic prescribing information addresses this in three places worth knowing.

On mechanism, it states that semaglutide "causes a delay of early postprandial gastric emptying, thereby reducing the rate at which glucose appears in the circulation postprandially."

On who should not take it, the label says Ozempic "is not recommended in patients with severe gastroparesis." That is not a contraindication, but it is a clear signal, and it matters for anyone with long-standing diabetes who may already have autonomic damage affecting the stomach.

Under postmarketing experience, the gastrointestinal reactions list includes "ileus, intestinal obstruction, severe constipation including fecal impaction." Postmarketing reports describe events observed after approval; they do not establish that the drug caused them or give a rate. They do tell you what to watch for.

What does the research show?

The most-cited analysis is a 2023 research letter by Sodhi and colleagues in JAMA (2023;330(18):1795-1797). It used a claims database to compare people prescribed a GLP-1 receptor agonist for weight loss with people prescribed bupropion-naltrexone, another weight-loss drug, which makes the comparison group more similar in intent than a general population would be.

The cohort included 613 semaglutide users, 4,144 liraglutide users, and 654 people on bupropion-naltrexone. The adjusted hazard ratios were:

Pancreatitis: 9.09 (95% CI 1.25 to 66.00)
Bowel obstruction: 4.22 (95% CI 1.02 to 17.40)
Gastroparesis: 3.67 (95% CI 1.15 to 11.90)
Biliary disease: 1.50 (95% CI 0.89 to 2.53), not statistically significant

Read those confidence intervals before the point estimates. A range of 1.25 to 66.00 for pancreatitis is compatible with a small increase or an enormous one; it mostly tells you the event count was tiny. The same caution applies to the gastroparesis figure. The finding is a signal worth taking seriously, not a precise risk estimate, and an observational analysis cannot fully separate the drug from the population taking it.

The practical translation: these events are uncommon in absolute terms, and they appear to occur more often on GLP-1 medications than on the comparator. Both halves of that sentence are load-bearing.

Which symptoms should actually worry you?

Nausea in the first weeks, and after each dose increase, is the norm. It typically improves as you stay at a dose. Our guide to managing Ozempic nausea covers the usual measures.

These are different, and warrant a call to your prescriber:

Vomiting that keeps you from holding down fluids, or vomiting food eaten many hours or a day earlier.
Nausea and fullness that persist rather than settling after two to three weeks at a stable dose.
Weight loss driven by inability to eat rather than by reduced appetite.
Signs of dehydration: dizziness on standing, dark urine, urinating far less than usual.

Seek urgent care for severe, persistent abdominal pain, especially pain that radiates to the back, which raises the question of pancreatitis; for abdominal pain with vomiting and no bowel movement or passage of gas, which raises the question of obstruction or ileus; or for a rigid, distended abdomen.

What about surgery and endoscopy?

This is the setting where delayed emptying has the clearest practical consequence. Food left in the stomach during anesthesia raises the risk of aspiration.

Guidance has shifted. In June 2023, the American Society of Anesthesiologists advised holding weekly GLP-1 agonists for a week before a procedure. In October 2024, a multi-society guidance document from the ASA together with the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity, and SAGES revised that position: most patients can continue their GLP-1 medication before elective surgery, while patients at highest risk of gastrointestinal effects should follow a liquid diet for 24 hours beforehand or take other precautions.

The action item is unchanged either way. Tell the surgeon, the anesthesiologist, and the endoscopist that you take this medication, and do it when the procedure is booked rather than on the day.

How to lower your risk

Escalate slowly. Most severe gastrointestinal symptoms follow rapid dose increases. There is no prize for reaching the top dose quickly.
Do not use compounded or unregulated semaglutide where dosing accuracy is not guaranteed.
Treat constipation early. Severe constipation and fecal impaction appear in the postmarketing list, and they are largely preventable with fluid, fiber, and movement.
Tell your prescriber about any existing gut condition, particularly diabetic gastroparesis, prior bowel obstruction, or a history of pancreatitis.
Eat smaller meals, more slowly. The stomach is emptying more slowly; the intake should match. See foods to avoid on Ozempic.

The bottom line

Ozempic slows gastric emptying by design, and that alone is not gastroparesis. Diagnosed gastroparesis on GLP-1 medications appears to be uncommon but more frequent than on a comparator drug, with a reported hazard ratio of 3.67 and a wide confidence interval that leaves the true magnitude unsettled.

The label already states that Ozempic is not recommended in severe gastroparesis, and lists ileus, obstruction, and severe constipation in postmarketing reports. Escalate the dose slowly, treat constipation before it becomes a problem, tell every proceduralist that you take it, and escalate to your prescriber if vomiting or fullness persists past a few weeks at a stable dose. Our overview of long-term Ozempic side effects covers the wider picture, and glp1.md covers how the class behaves as a whole.

Last updated: August 2026. This article is for informational purposes only and does not constitute medical advice. Do not stop or change a prescribed medication without speaking to your prescriber. Seek urgent care for severe abdominal pain, persistent vomiting, or an inability to keep fluids down.